Clinical trial
A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
NCT05169684 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 14, 2022
- Completion date
- December 6, 2023
- Enrollment
- 10 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.